Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPAL
ISRCTN13526307Phase 3Active, not recruiting
- Sponsor
- Norfolk and Norwich University Hospitals NHS Foundation Trust
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lansoprazole in idiopathic pulmonary fibrosis (IPF), sponsored by Norfolk and Norwich University Hospitals NHS Foundation Trust. Primary endpoint: Predicted forced vital capacity. Started Jun 2021; status: active, not recruiting.
02
Drugs
lansoprazole
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ISRCTN13526307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13526307.